Skip to main content
. 2010 Oct 5;103(9):1407–1414. doi: 10.1038/sj.bjc.6605925

Figure 3.

Figure 3

Outcome to bevacizumab-containing therapy in CRC by serum Ang-2 (n=34). (A) Response by serum Ang-2. (B) PFS by serum Ang-2. (C) OS by serum Ang-2. Ang-2, angiopoietin-2.